Prognosis in UC After First Biological (biological)

Tampere University Hospital

Status: Completed

Conditions: Ulcerative Colitis

Treatments: Biological: infliximab, adalimumab, golimumab, vedolizumab, ustekinumab

Study type: Observational

Funder types: Other

Identifiers

NCT05530122

R20543

Details and patient eligibility

About

To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.

Full description

UC patients treated with at least one biological in Tampere University Hospital between January 2009 and January 2020 were identified and reviewed from patient records.

Enrollment: 192 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated for ulcerative colitis for the first trial of biological

Exclusion criteria

• Age under 16 years